Ligand Pharmaceuticals News

Ligand Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C SAN DIEGO -- -- Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline plc announced today that it has submitted regulatory applications in the United States and European Union ... (more)

The conference takes place at the Encore at Wynn Las Vegas. A live webcast of the presentation will be available on the Company's website www.ligand.com . A replay of the presentation will be archived on the site for 30 days.

"2012 has opened strong for Ligand and our partnered programs. GSK has confirmed the planned sNDA filing for Promacta in Hepatitis C based on the positive Phase 3 ENABLE Trials.